ALK-Abelló A/S, commonly known as ALK, is a Denmark-based pharmaceutical company specializing in the development and manufacturing of allergy immunotherapy (AIT) products for the prevention and treatment of allergies. Founded in 1923, ALK has a global presence, with operations in 46 countries. The company's product portfolio includes sublingual immunotherapy tablets, sublingual immunotherapy drops, and subcutaneous immunotherapy injections, targeting common allergens such as grass pollen, ragweed pollen, and house dust mites. In November 2024, ALK entered into a licensing agreement to commercialize Neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis), outside the U.S., Australia, New Zealand, Japan, and China. :contentReference[oaicite:0]{index=0}